Clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) has received guidance from the U.S. Food and Drug Administration (FDA) for a Phase 3 trial of Zygel to treat Fragile X syndrome (FXS).   FXS is a rare genetic disability that causes inherited intellectual disability as well as autism spectrum disorders.    In the Phase 3 trial, called RECONNECT, the efficacy and safety profile of Zygel will be evaluated in children and adolescents with FXS. Zygel, which is a gel that delivers CBD (non-euphoric cannabinoid) through the skin, targets the behavioral effects of FXS.